A simple heart measurement may help predict outcomes in children awaiting liver transplants
Children with advanced liver disease face many challenges while awaiting a liver transplant. Although the focus is often on the liver itself, growing evidence suggests that cirrhosis can also affect the heart, increasing the risk of complications before and after a transplant. New research from investigators at Texas Children's Hospital and Baylor College of Medicine identified a readily available heart measurement that may help clinicians better predict which children are at greatest risk for serious complications.
Published in the Journal of Hepatology, the study found that an elevated left ventricular mass index (LVMI), a measurement obtained during a routine echocardiogram, is strongly associated with worsening illness, transplant-related complications and mortality in infants and children with cirrhosis.
The study was led by Dr. Dalia A. Bashir, member of Texas Children’s Research Institute (TCRI) and assistant professor of pediatrics at Baylor, and Dr. Moreshwar S. Desai, also member of the TCRI and an associate professor of pediatrics at Baylor. The investigators sought to better understand a condition known as cirrhotic cardiomyopathy, a form of heart dysfunction that develops in some patients with advanced liver disease. Although cirrhotic cardiomyopathy is increasingly recognized in adults, it remains poorly defined and understudied in children.
“In children with cirrhosis, the heart is often considered only when a problem becomes clinically apparent,” said Bashir. “Our findings show that meaningful structural changes may already be present and that a measurement available on a routine echocardiogram can help us recognize those changes earlier.”
To address this gap, the team analyzed data from 386 children listed for liver transplantation between 2011 and 2021, including 226 patients with cirrhosis. Researchers examined echocardiograms, clinical outcomes, pathology findings and transplant-related complications to foresee patient outcomes.
The investigators discovered that approximately one-quarter of patients with cirrhosis had left ventricular hypertrophy, a thickening of the heart muscle, compared with just 4% of non-cirrhotic patients.
Autopsy analyses provided additional insights. The researchers found that hearts from cirrhotic patients frequently showed myocardial fibrosis, a form of scarring within the heart muscle, as well as enlargement and thickening affecting both ventricles. These findings suggest that cirrhosis can trigger significant structural changes in the heart long before transplantation occurs, including larger and heavier hearts.
Among the various echocardiographic measurements evaluated, LVMI emerged as the strongest predictor of clinical outcomes. Higher LVMI values were associated with an increased likelihood of waitlist decompensation, serious post-transplant complications, and death. These associations remained significant even after accounting for traditional measures of liver disease severity, including Pediatric End-Stage Liver Disease (PELD) and Model for End-Stage Liver Disease (MELD) scores.
The findings also demonstrated that combining LVMI with existing PELD and MELD scoring systems improved clinicians’ ability to predict waitlist deterioration and serious post-transplant complications compared with liver disease scores alone.
“What stood out was that LVMI provided prognostic information beyond the liver disease scores we already use,” said Desai. “It gives us a practical window into how the heart is responding to cirrhosis and may help identify children who are more vulnerable while waiting for a transplant.”
The team identified clinically meaningful LVMI thresholds associated with risk. Researchers also found that LVMI tracked closely with how well the heart tolerated the stress of major surgery. Patients with higher LVMI required more medications to support circulation during and after liver transplantation, suggesting that the measurement reflects the heart’s ability to respond under stress.
Notably, LVMI changed over time. In many children with cirrhosis, heart muscle mass increased while they remained on the transplant waiting list. Patients whose LVMI continued to worsen experienced higher rates of complications and death. Encouragingly, LVMI often improved after successful liver transplantation, suggesting that some of the cardiac changes may be reversible when liver function is restored.
“The increase in LVMI while children were awaiting a transplant, followed by improvement after the transplant in many patients, suggests that the heart is responding dynamically to the burden of liver disease,” said Bashir.
Because echocardiography is already a routine component of pretransplant evaluation, LVMI could offer a practical and noninvasive way to identify children at risk of poor outcomes and help guide clinical decision-making. The researchers suggest that incorporating heart assessments may ultimately improve transplant timing and patient management.
“Our findings raise awareness of this previously under-recognized co-morbidity amongst those taking care of infants and children with cirrhosis,” said Desai. “Knowledge gleaned from the current study and our past published reports informs risk stratification, organ allocation strategies, pretransplant planning and anticipating and managing intraoperative and postoperative complications.”
The study highlights the close relationship between liver disease and heart health in children and provides evidence that a simple echocardiographic measurement may help clinicians better identify vulnerable patients and optimize care before and after a liver transplant.
###
Other contributors to this work include Sameer Thadani, Taylor Nack, Nour Gebara, Noelle Gorgis, Manpreet Virk, Anna M. Banc Husu, Tam T. Doan, Nhu Thao Nguyen Galvan, Muhammad Umair M. Mian, Kathleen Hosek, Kelby Fuller, Kalyani R. Patel, Divya Sabapathy, Sammie T. James, Thomas Fogarty III, Daniel J. Penny, Duy Dinh, and Curtis E. Kennedy. The authors are affiliated with one or more of the following institutions: Texas Children’s Hospital, Baylor College of Medicine, Children's Hospital of Philadelphia, University of Pennsylvania, and the University of Missouri School of Medicine.